<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719170</url>
  </required_header>
  <id_info>
    <org_study_id>SDR 18-151</org_study_id>
    <nct_id>NCT03719170</nct_id>
  </id_info>
  <brief_title>Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program</brief_title>
  <acronym>RaPPID</acronym>
  <official_title>Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VHA Pharmacy Benefits Management Services VA Center For Medication Safety</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders,&#xD;
      such as chronic heartburn. These medications are widely used by Veterans, with over 11&#xD;
      million 30-day prescriptions being filled each year. Though they are highly effective,&#xD;
      long-term use of PPIs may be harmful. For this reason, experts recommend that PPIs be stopped&#xD;
      in patients who do not have a clear need for these medications. Unfortunately, PPIs continue&#xD;
      to be overused. To address this issue, the VA is implementing a national program to&#xD;
      de-prescribe (i.e., reduce the dose of, or stop) PPIs. In this study, the investigators will&#xD;
      be evaluating this national program by assessing: (a) how successfully the program was&#xD;
      implemented; (b) understanding how effective the program was in improving appropriate use of&#xD;
      PPIs; and, (c) ensuring no unintended consequences (such as peptic ulcer bleeding) occurred&#xD;
      with PPI de-prescribing. This study addresses a potential safety concern for Veterans and&#xD;
      aligns with VA's broader goal of de-implementing low-value care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Proton pump inhibitors (PPIs) are among the most commonly prescribed medications&#xD;
      in the VHA, accounting for over 11 million 30-day prescriptions and nearly $50 million in&#xD;
      medication costs annually. Though effective for treatment of acid-related disorders such as&#xD;
      gastroesophageal reflux disease, PPIs have been associated with a number of potential harms&#xD;
      in observational studies (e.g., dementia, chronic kidney disease, fractures), and increased&#xD;
      mortality in Veterans. Nonetheless, PPIs continue to be used without an appropriate&#xD;
      indication or for longer and at higher doses than necessary. Accordingly, VHA Pharmacy&#xD;
      Benefits Management Services (PBM) will deploy RaPPID - a national Randomized PPI&#xD;
      De-prescribing program - in Fiscal Year 2018 targeting patients for whom a short course of&#xD;
      PPI is likely sufficient. This program will comprise activation of Clinical Pharmacy&#xD;
      Specialists, provider education and academic detailing, and patient education. In partnership&#xD;
      with PBM, the investigators propose to conduct an evaluation of this national program in a&#xD;
      cluster-randomized design.&#xD;
&#xD;
      Objectives: (1) assess the impact of the de-prescribing program on important clinical&#xD;
      outcomes, and to understand how and why these outcomes were achieved or not achieved&#xD;
      (outcomes and process evaluation); (2) assess the economic effects of the de-prescribing&#xD;
      program (economic evaluation).&#xD;
&#xD;
      Methods: The investigators will then assess the impact of RaPPID on PPI use (primary outcome)&#xD;
      in a cluster randomized design (cluster = Veterans Integrated Service Network (VISN). The&#xD;
      investigators will also assess a variety of unintended effects, including impact of reduced&#xD;
      PPI use on upper GI symptoms and complications such as upper GI bleeding. Furthermore, the&#xD;
      investigators will use process evaluation approaches to understand why and how the program&#xD;
      was effective or ineffective in specific contexts. Finally, the investigators will use data&#xD;
      from the outcomes evaluation of this proposal to estimate the budget impact of RaPPID, taking&#xD;
      into account the impact of the program on VHA and non-VHA healthcare utilization.&#xD;
&#xD;
      Impact: RaPPID will be among the largest concerted efforts at de-prescribing ever undertaken&#xD;
      in VHA. Prospective evaluation of the program therefore presents a unique opportunity not&#xD;
      only to enhance the program itself, but also to gain insights about how to reduce the use of&#xD;
      low-value services more broadly, a key VHA priority for the coming decade. Importantly, the&#xD;
      prospective, controlled study design the investigators propose will also allow us to make&#xD;
      strong claims about whether PPIs cause the putative adverse effects to which they have been&#xD;
      linked. Ultimately, this evaluation will provide not only valuable insight into the benefits&#xD;
      and harms of a national effort to appropriately de-prescribe PPIs, but also broader lessons&#xD;
      about how to effectively undertake other such interventions to de-implement entrenched&#xD;
      clinical practices in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A cluster-randomized (by Veterans Integrated Service Networks or VISN) pragmatic trial of the provider-centered intervention versus pragmatic control.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPI Prescribing (H1)</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of days proton pump inhibitors are prescribed in the 12 months following the index visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208266</enrollment>
  <condition>Proton Pump Inhibitors</condition>
  <arm_group>
    <arm_group_label>De-prescribing Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No De-prescribing Program</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and will not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PPI De-prescribing Program</intervention_name>
    <description>The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.</description>
    <arm_group_label>De-prescribing Program</arm_group_label>
    <other_name>RaPPID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Chronic PPI users defined as 90-day prescription during the 120-day period prior to a&#xD;
        scheduled VA primary care visit who receive:&#xD;
&#xD;
          1. Once-daily PPI with&#xD;
&#xD;
               -  No clear indication for PPIs, OR&#xD;
&#xD;
               -  Uncomplicated GERD OR&#xD;
&#xD;
          2. Twice-daily PPI for any indication except Zollinger-Ellison&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients taking once-daily PPIs will be exclued if they have one or more of the following&#xD;
        characteristics:&#xD;
&#xD;
          -  Eosinophilic esophagitis&#xD;
&#xD;
          -  Esophagitis&#xD;
&#xD;
          -  Esophageal ulcer&#xD;
&#xD;
          -  Esophageal stenosis/stricture&#xD;
&#xD;
          -  Dysphagia (other than oropharyngeal)&#xD;
&#xD;
          -  Barrett's esophagus&#xD;
&#xD;
          -  Peptic ulcer&#xD;
&#xD;
          -  Zollinger-Ellison&#xD;
&#xD;
          -  Idiopathic pulmonary fibrosis&#xD;
&#xD;
          -  NSAID + age &gt; 65 yrs, 2nd NSAID, aspirin, anti-thrombotic, OR corticosteroid&#xD;
&#xD;
          -  Aspirin + age 60 yrs, NSAID, anti-thrombotic, OR corticosteroid&#xD;
&#xD;
          -  Pancreatic enzyme replacement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameer D. Saini, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System, Ann Arbor, MI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System, Ann Arbor, MI</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spechler SJ, Hunter JG, Jones KM, Lee R, Smith BR, Mashimo H, Sanchez VM, Dunbar KB, Pham TH, Murthy UK, Kim T, Jackson CS, Wallen JM, von Rosenvinge EC, Pearl JP, Laine L, Kim AW, Kaz AM, Tatum RP, Gellad ZF, Lagoo-Deenadayalan S, Rubenstein JH, Ghaferi AA, Lo WK, Fernando RS, Chan BS, Paski SC, Provenzale D, Castell DO, Lieberman D, Souza RF, Chey WD, Warren SR, Davis-Karim A, Melton SD, Genta RM, Serpi T, Biswas K, Huang GD. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. N Engl J Med. 2019 Oct 17;381(16):1513-1523. doi: 10.1056/NEJMoa1811424.</citation>
    <PMID>31618539</PMID>
  </results_reference>
  <results_reference>
    <citation>Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ, Yang YX, Laine L, Weissman A, Saini SD. Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey. Am J Gastroenterol. 2020 May;115(5):689-696. doi: 10.14309/ajg.0000000000000558.</citation>
    <PMID>32091419</PMID>
  </results_reference>
  <results_reference>
    <citation>Simonov M, Abel EA, Skanderson M, Masoud A, Hauser RG, Brandt CA, Wilson FP, Laine L. Use of Proton Pump Inhibitors Increases Risk of Incident Kidney Stones. Clin Gastroenterol Hepatol. 2021 Jan;19(1):72-79.e21. doi: 10.1016/j.cgh.2020.02.053. Epub 2020 Mar 6.</citation>
    <PMID>32147588</PMID>
  </results_reference>
  <results_reference>
    <citation>Laine L. Colonoscopy for Lower Gastrointestinal Bleeding-Time Is Not of the Essence. Gastroenterology. 2020 Jan;158(1):38-39. doi: 10.1053/j.gastro.2019.11.009. Epub 2019 Nov 12.</citation>
    <PMID>31730767</PMID>
  </results_reference>
  <results_reference>
    <citation>Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, Leontiadis GI, Abraham NS, Calvet X, Chan FKL, Douketis J, Enns R, Gralnek IM, Jairath V, Jensen D, Lau J, Lip GYH, Loffroy R, Maluf-Filho F, Meltzer AC, Reddy N, Saltzman JR, Marshall JK, Bardou M. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019 Dec 3;171(11):805-822. doi: 10.7326/M19-1795. Epub 2019 Oct 22.</citation>
    <PMID>31634917</PMID>
  </results_reference>
  <results_reference>
    <citation>Saffouri E, Blackwell C, Laursen SB, Laine L, Dalton HR, Ngu J, Shultz M, Norton R, Stanley AJ. The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2020 Jan;51(2):253-260. doi: 10.1111/apt.15541. Epub 2019 Oct 23.</citation>
    <PMID>31642558</PMID>
  </results_reference>
  <results_reference>
    <citation>Laine L. Timing of Endoscopy in Patients Hospitalized with Upper Gastrointestinal Bleeding. N Engl J Med. 2020 Apr 2;382(14):1361-1363. doi: 10.1056/NEJMe2002121.</citation>
    <PMID>32242363</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee MW, Pourmorady JS, Laine L. Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020 May;115(5):662-670. doi: 10.14309/ajg.0000000000000495.</citation>
    <PMID>31972617</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell EV 3rd, Muniraj T, Aslanian HR, Laine L, Jamidar P. Musculoskeletal Pain Symptoms and Injuries Among Endoscopists Who Perform ERCP. Dig Dis Sci. 2021 Jan;66(1):56-62. doi: 10.1007/s10620-020-06163-z. Epub 2020 Mar 6.</citation>
    <PMID>32144599</PMID>
  </results_reference>
  <results_reference>
    <citation>Shung D, Laine L. Machine Learning Prognostic Models for Gastrointestinal Bleeding Using Electronic Health Record Data. Am J Gastroenterol. 2020 Aug;115(8):1199-1200. doi: 10.14309/ajg.0000000000000720.</citation>
    <PMID>32530828</PMID>
  </results_reference>
  <results_reference>
    <citation>Laursen SB, Oakland K, Laine L, Bieber V, Marmo R, Redondo-Cerezo E, Dalton HR, Ngu J, Schultz M, Soncini M, Gralnek I, Jairath V, Murray IA, Stanley AJ. ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study. Gut. 2021 Apr;70(4):707-716. doi: 10.1136/gutjnl-2019-320002. Epub 2020 Jul 28.</citation>
    <PMID>32723845</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelly CR, Laine LA, Wu GD. Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment. Gastroenterology. 2020 Dec;159(6):2004-2006. doi: 10.1053/j.gastro.2020.08.039. Epub 2020 Aug 22.</citation>
    <PMID>32841646</PMID>
  </results_reference>
  <results_reference>
    <citation>Vyas M, Celli R, Singh M, Patel N, Aslanian HR, Boffa D, Deng Y, Ciarleglio MM, Laine L, Jain D. Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction. Hum Pathol. 2020 Nov;105:67-73. doi: 10.1016/j.humpath.2020.08.007. Epub 2020 Sep 14.</citation>
    <PMID>32941964</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>proton pump inhibitors</keyword>
  <keyword>program evaluation</keyword>
  <keyword>low-value care</keyword>
  <keyword>de-implementation</keyword>
  <keyword>patient safety</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

